Pyrrolopyrimidine derivatives comprise a class of biologically active heterocyclic compounds that are well known to play a critical role in pharmaceutical drug design and health care. The pyrrolopyrimidines serve as promising scaffolds that were found in a number of biologically active compounds including antibiotics, anti-inflammatory, anti-viral and anticancer. Researchers were inspired to develop novel pyrrolopyrimidine derivatives for the treatment of Cancer. Currently several pyrrolopyrimidines are available commercially as anticancer drugs. The present review article offers a detailed account on the development of pyrrolopyrimidine derivatives with anticancer potential with emphasis on their activity as targeted kinase inhibitors.
INTRODUCTION
Pyrrolopyrimidine derivatives occupy an important place among various heterocyclic systems because they include compounds with different types of biological activity. Furthermore, these bicyclic compounds represent structural analogues of biogenic purines and hence they can be regarded as potential antimetabolites in nucleic acid metabolism. These data have served and continue to serve as a basis for the synthesis of a wide variety of derivatives of pyrrolopyrimidines in order to discover physiologically active substances among them. 1 Pyrrolopyrimidines have aroused recent attention from chemical and biological view points since they have useful properties as ant-inflammatory 2 , antimicrobial 3, 4 , antiviral 5 and anti-cancer [6] [7] [8] [9] [10] [11] . They have useful properties as antimetabolites in purine biochemical reactions. Several mechanisms are also involved in their cytotoxic activities as being antifolate inhibitors of dihydrofolate reductases 12 .
The pyrrolopyrimidine scaffold is being extensively investigated and in the last few years many of such compounds resulted active as kinase inhibitors. The present review highlights the anticancer activity of pyrrolopyrimidine derivatives through inhibition of specific kinase enzymes. pyrimidines with α-halogenated ketones or aldehydes and is combined with the subsequent pyrrole condensation in a one-pot procedure (Figure 1 ).
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N1-Substituted-2-amino-3-cyanopyrroles are essential precursors for the preparation of pyrrolo [2,3-d] pyrimidines bearing reactive functionalities such as amino or oxo group at C4. N1-substituted pyrrole with alkyl and benzyl groups was utilized and described in literature as precursors to prepare the N7-unsubstituted pyrrolo [2,3-d] pyrimidine. 16, 17 A dealkylation reaction in polyphosphoric acid, followed by ammonium hydroxide neutralization was descriped for elimination of N1 alkyl substitution. The Aryl protecting group was removed with AlCl3 in toluene to give the final unsubstituted derivatives. 16, 17 2-amino-3-cyanopyrrole could be refluxed in 85% formic acid or formamide to afford the corresponding pyrrolo [2,3-d] pyrimidine-4-one or pyrrolo [2,3-d] pyrimidine-4-amine respectively. 1, 16 Pyrrolopyrimidines as kinase inhibitors and potential anticancer agents
Protein Kinase inhibitors
Protein kinases play an important role in signal transduction pathways that regulate numerous cellular functions, including proliferation, differentiation, migration, apoptosis, and angiogenesis. The up regulation of the signal transduction pathways is observed in tumor cells, this makes inhibitors of protein kinases that target the up-regulated pathways attractive candidates for cancer therapy. 13, 14 Kinase inhibitors have played an increasingly important role in the treatment of cancer. A detailed study on the role of pyrrolopyrimidine derivatives in inhibition of protein kinases is demonstrated below.
FAK
Focal adhesion kinase (FAK) is a tyrosine kinase that plays an important role in cellular movement and survival pathways. FAK is a potential target for the treatment of both primary cancers and the prevention of tumor metastasis. [15] [16] [17] (Compound 1) showed submicromolar inhibitory activity against FAK, and a cocrystal structure of this with FAK was successfully obtained (pdb code 2ETM).
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Compound 1
Later on, A series of 2-amino-9-aryl-7H-pyrrolo [2,3-d] pyrimidines were designed and synthesized as focal adhesion kinase (FAK) inhibitors using molecular modeling in conjunction with a cocrystal structure. This study resulted in the identification of potent FAK inhibitors. (Compound 2) possessed single-digit nanomolar IC50 and represents one of the most potent FAK inhibitors discovered.
19
Compound 2 (IC50=0.004 µM)
Tie-2
Tie-2 is a receptor tyrosine kinase (RTK) that is essential for the formation of the embryonic vasculature and is implicated in tumor angiogenesis. 6, 25, 26 Pyrrolopyrimidines have been reported to bind to the Tie-2 kinase domain (Figure 2 ) [27] [28] [29] However, no specific details were available with regard to Tie-2 kinase/cellular potency, selectivity, SAR, ADMET and in vivo attributes. Later on there have been several reports on non-pyrrolopyrimidine based Tie-2 inhibitors 30,31 but few showed kinase selectivity at the time.
In 2013, novel pyrrolopyrimidines were evaluated as potent Tie-2 inhibitors with good selectivity against other key angiogenesis kinases and adequate ADMET properties. 32 The ketophenyl urea derivative (Compound 3) was identified as reversible and ATP competitive Tie-2 inhibitor with potent activity in wholecell assays.
Compound 3
IGF-1R
The IGF-1R signaling pathway is activated in a wide range of human cancers including prostate 33 , breast 34 , colon and pancreas 35 by the overexpression of IGF-1R or its ligands IGF-1 and 2 and/or by the decrease of levels of IGF binding proteins. Inhibition of IGF-1R through many approaches resulted in decreased proliferation and survival of tumor cells in vitro and in vivo. 
Compound 5
Later on various IGF-1R inhibitors have been developed based on the fact that the link to cancer was through targeting the kinase activity by binding within the adenosine triphosphate (ATP) binding site 38, 39 . Of these, linsitinib is the most advanced and it is curently in phase II studies, in a wide range of cancers, in combination with other treatments 40, 41 . linsitinib workers at Novartis had described the identification of the structurally related 5-phenyl-4-aminopyrrolopyrimidine derivative NVP-AEW541; (Compound 6) which has been used extensively as an IGF-1R inhibitor tool in a various preclinical investigation [42] [43] [44] Optimization of this target resulted in the identification of (Compound 7). Compared with NVP-AEW541, Compound 7 exhibited increased IGF-1R potency with an IC 50 of 13 nM 45 .
m-TOR
The mammalian target of rapamycin mTOR is a serine/therionine-specific protein kinase that belongs to the family of phosphatidylinositol Inhibition of mTOR signaling can be used for the treatment of solid tumors with mutations or deletion of the tumor suppressor phosphatase and tensin homolog (PTEN) gene. 47 Guided by structure-based design, a series of mTOR selective N-7 substituted imidazolopyrimidines were evaluated and synthesized, the SAR was expanded to include N-Mepyrrolopyrimidine and N-Me-pyrazolopyrimidine scaffolds and these similar ring systems have been reported as potent PI3K and/or mTOR inhibitors [48] [49] [50] [51] [52] .
In 2013, W. Lee et al. were able to evaluate a variety of pyrrolopyrimidine derivatives as mTOR inhibitors with selectivity against PI3K (Compound 8) 53 . Numerous research groups are actively investigating the role and function of BTKs as well as the potent and selective BTK inhibitors as potential tool compounds and drug candidates. 57 BTK is considered a promising target for the therapeutic intervention of several diseases, including inflammatory diseases and cancer. A series of novel reversible BTK inhibitors were designed based on the structure of the recently reported preclinical drug
NVP-
RN486 (Compound 9).
Based on the study of the binding mode of RN486, new inhibitors that utilized pyrrolo [2,3-d] pyrimidine were designed to conformationally restrain key pharmacophoric groups within the molecule. Compound 10 displayed superior activity both in BTK enzyme (IC50 = 4.8 nM) and cellular inhibition (IC50 = 17 nM) assays to that of RN486 (IC50 = 27.3 nM) ( Figure  3) . 58 .
SFKs
SFKs (Src family kinases) are a family of cytoplasmic tyrosine kinases that are overexpressed and hyperactivated in various pathologies, including cancer. Among SFKs, c-Src is involved in pathways that controls cell proliferation, migration, .and angiogenesis 59 . c-Src is a good therapeutic target, and many small molecule Src inhibitors have been developed for the treatment of different tumors. 60 Several small molecule inhibitors of SFKs are currently investigated in clinical trials. Pyrrolopyrimidine compounds CGP76030 (Compound 11) and CGP77675 (Compound 12) were reported to have inhibitory activity at nanomolar levels in osteoporosis and cancer models in vitro and in vivo against c-Src 61 . Recently in 2017, c-Src has been shown to be frequently overexpressed also in Glioblastoma multiforme (GBM), a brain tumor characterized by a high degree of proliferation, angiogenesis, necrosis, and invasiveness. A novel series of pyrrolo [2,3-d] pyrimidine compounds were found to have activity against GBM. Such compounds were able to act as ATP competitive inhibitors of Src. Enzymatic assays against a mini-panel of kinases showed an unexpected high selectivity of these pyrrolo [2,3-d] pyrimidines for Src since they did not show any activity against other tyrosine kinases.
Finally, the derivatives were tested for their antiproliferative potency on U87 GBM cell line. The most active was Compound 13, with an IC50 value of 7.1 µM 62 .
CGP76030 CGP77675 (Compound 11) (Compound 12)
MPs 1
Monopolar spindle 1 (Mps1), also known as TTK, is a dual specificity protein kinase that phosphorylates tyrosine, serine, or threonine residues with a critical role during mitosis and is highly expressed in cancer cells. 63 65 , Due to the high molecular weight and polar surface area of these leads de novo Structure design using molecular modeling, followed by conformational restriction and scaffold hopping led to new pyrrolopyrimidine inhibitors. These scaffolds have been shown to be potent Mps1 inhibitors that possess submicromolar cellular cytotoxicity. The most active in the pyrrolopyrimidine series is (Compound 16) IC50=20 nM (Figure 4) . These new leads provide the basis for developing more potent, novel inhibitors of Mps1 with drug-like properties 68 .
Compound 13
Various studies reported that high levels of Mps1 protein have been correlated with high histologic grade in breast cancer, while reducing Mps1 levels in BC cells resulted in induction of apoptosis, and decreased ability of BC cells to grow as xenografts in nude mice. 69, 70 , suggesting a potential new therapeutic target for aggressive breast cancers. 66 Mps1/TTK regulates cell cycle progression 63,72. These observations suggest that pharmacological inhibition of Mps1/TTK may be a promising targeted cancer therapeutic. Several Mps1/TTK inhibitors have been developed in recent years. 66, 73 In 2017, novel small molecule Mps1/TTK inhibitors have been identified as potential targeted therapies for breast cancers, (Compound 17) inhibits in vitro kinase activity of Mps1 with an IC50 value of 0.809 µM and (Compound 18) which is the most promising in the study with an IC50 value of 0.356µM. 74 Future indepth investigations of both anticancer activities and safety profiles of these Mps1 inhibitors are warranted.
CDK
Cyclin-dependent kinases (CDKs) are serine/threonine kinases that regulate cell division, transcription, apoptosis, and differentiation 75 . CDK inhibitors have attracted ther attention for their potential as anticancer therapeutics. (CDKs) 4 and 6 are enzymes that have been shown to promote cell division and multiplication in both normal and cancer cells. Many cancer cells have shown abnormalities that increase the activity of CDK, leading to the inactivation of certain tumor suppressor genes. 76, 77 . This has led to the idea that inhibiting CDK4 will slow the growth of tumors by reactivating these tumor suppressors. Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of breast cancer. 78 The pyrrolopyrimidine based Ribociclib (Compound 19) previously known as LEE 011 is an inhibitor of CDK4 and CDK6, developed by Novartis and Astex Pharmaceuticals and is being studied as a treatment for drug-resistant cancers and approved in March 2017 by the US FDA as first-line treatment for metastatic breast cancer in combination with any aromatase inhibitor. This will be marketed as Novartis Kisqali® 79, 80 .
Novartis Kisqali® (ribociclib, LEE011) (Compound 19)
Aurora kinase
The Aurora proteins is a small family of serine/threonine kinases that have become prominent targets for the modulation of cell cycles. Aurora-A and -B kinases are overexpressed in human tumors including breast, colon, lung, ovarian, and pancreatic cancers. J.-Y. 
ACK1
Activated Cdc42-associated tyrosine Kinase 1(ACK1) is a non-receptor tyrosine kinase that attracted substantial interest as a target for drug discovery research in recent years. [82] [83] [84] [85] Amplification of the ACK1 gene in primary tumors is correlated with poor prognosis 86 . A number of new heterocyclic structures were synthesized and evaluated. Pyrrolopyrimidine (Compound 21) proved to be a potent ACK1 inhibitor in vitro (ACK1 Ki = 0.006 µM). A large number of substituents were introduced at the para-position of the 6-phenyl ring, significant improvements in both biochemical and cellular ACK1 led to the identification of potent and selective dithiolane inhibitor (Compound 22) with good kinase selectivity, and a suitable in vitro metabolic profile ( Figure 5) . Unfortunately, the pharmacokinetic profile of this was poor and prevented this inhibitor from being further evaluated in tumor xenograft studies 87 .
JAK
Janus kinases (JAKs) are non-receptor tyrosine kinases that play important roles in signaling processes in mammalian cells such as cell growth, survival, development and differentiation. 88, 89 . Four isoforms of JAK have been identified, including JAK1, JAK2, JAK3 and tyrosine kinase 2 TYK2. 90 Each JAK kinase has significant role in the pathogenesis of immune-related diseases and in hematological cancer signaling in various cells. 91 95 The pyrrolopyrimidine group of Ruxolitinib (Compound 24) and Tofacitinib (Compound 25), are FDA approved as a JAK1/2 inhibitor and a JAK3 inhibitor, respectively. 96 In 2016, various analogues were designed and synthesized based on a 4-triazole-pyrrolopyrimidine skeleton for the discovery of selective and novel JAK2 inhibitors. Compound 26 (IC50 = 41.9 nM) and with fold selectivity: JAK1/2 = 10.6 and JAK3/2= 58.1 was found to be a novel potent and selective JAK2 inhibitor. 97 This novel JAK2 selective inhibitor may be a potential lead for new drug discovery via development of more potent and selective JAK2 inhibitors.
PDK1
3-Phosphoinositide-dependent kinase 1 (PDK1) is a biological target that has attracted a considerable interest in recent years. As PDK1 plays a key regulatory role within the PI3K/Akt signalling pathway, targeted inhibition of this kinase provides an attractive target for the treatment of cancer. 98 In 2011, a study involved the discovery of pyrrolopyrimidine analogues as potent PDK1 inhibitors. The study revealed that Compound 27 was selective inhibitor of PDK1 with Ki of 1 nM and >100-fold selectivity against PI3K/AKT-pathway kinases. et al., 2018, 2 (1), 1-19 http://aprh.journals.ekb.eg/ 9
Later on 2014, a first-generation series of substituted 2-anilino-7H-pyrrolopyrimidines (Compound 28) 100 were designed by a molecular modelling study in which the core of the inhibitor was bound to the ATP binding site of PDK1. Biological screening against PDK1 was performed, but only modest inhibition was observed. a series of second-generation analogues, with variation at the 4-position of the 7H-pyrrolopyrimidine scaffold were developed. Biological evaluation showed an overall increase in activity towards the PDK1 in comparison to the first-generation set. 4-Methoxy derivative (Compound 29) provides a potentially useful lead for the development of new PDK1 inhibitors 101 .
Compound 28
Compound 29
AKT Akt is a serine threonine kinase that is frequently deregulated in cancer, making it an attractive anticancer drug target. 102 Due to the strong rationale for targeting Akt in cancer, much effort has been made to identify Akt inhibitors with acceptable pharmaceutical properties. The most common approaches described to date have been through the development of compounds that are either ATP-competitive or that prevent the formation of the active enzyme. 103 A number of Akt inhibitors are currently being tested in clinical trials, including allosteric inhibitors of inactive Akt. [104] [105] [106] CCT128930 (Compound 30) is a potent ATPcompetitive AKT inhibitor discovered using fragment and structure-based approaches. It is a lead pyrrolopyrimidine exhibiting selectivity for AKT2 with IC50 = 6nM. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro. 107 Recently, in 2013 the benzylamide (Compound 31) that previously reported as an orally bioavailable inhibitor of Akt and was identified as a suitable starting point for further optimization as a result of collaboration of AstraZeneca, with Astex Therapeutics Ltd and the Institute of Cancer Research. 108, 109 Compound 31 served as a lead Akt inhibitor. A crystal structure of this bound to Akt1 suggested a possible vector for further substitution (PDB code 2X39), and was explored with a range of diverse substituents and chain lengths, leading to AZD5363 (Compound 32). This agent inhibits all Akt isoforms with a potency of <10 nM in vitro, and it showed pharmacodynamic and xenograft activity in vivo. It has potential in cancer therapy and is under clinical trials 110 
EGFR
The membrane bound epidermal growth factor receptor tyrosine kinase (EGFR) has been one of the most investigated kinases, since EGFR amplification or mutation has been noted in various cancer types. Only three pyrroloyrimidine based EGFR inhibitors have reached clinical trials, namely PKI-166(Compound 33) 111 , AEE-788 (Compound 34) 112, 113 , and TAK-285 (Compound 35) 114, 115 .
In 2014, S.J. Kaspersen et al. performed a study on the enzymatic inhibition potential of a series of chiral and non-chiral pyrrolopyrimidine based derivatives that have been investigated and optimized. New structures were identified having enzymatic IC50 values comparable to the commercial drug Erlotinib. These compounds were further evaluated towards a panel of 52 kinases revealing interesting Src-family kinase inhibitory activity, (Compound 36), the most active in the designed series against EGFR with IC50=0.1nM, confirming pyrrolopyrimidines as attractive drug candidates or lead structures. 116 A late focus on absorption, distribution, metabolism, excretion and toxicology (ADMET) is regarded as one of the main reasons for drug failure. 117, 118 Thus in 2015, the pyrrolopyrimidine (compound 36) have been evaluated and compared with the established drug Erlotinib in cellular assays towards 25 cancer cell lines and by ADME/tox profiling. This performed equally or better than the Erlotinib in most of the cases and the highest activity was seen towards lung and breast EGFR and HER2 119 .
In 2016, in an attempt to improve the ADMET properties of the designed structures, starting from lead et al., 2018, 2 (1), 1-19 http://aprh.journals.ekb.eg/ 11 VEGFR-2 is the predominant receptor in angiogenic signaling. differentiation, and survival as well as vessel permeability and dilation. 121 In order to develop new VEGFR inhibitors a series of pyrrolo [3,2- 
Pyrrolopyrimidines as multiple receptor tyrosine kinase inhibitors
Receptor tyrosine kinases (RTKs) such as vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and plateletderived growth factor receptor (PDGFR) have important functions in signal transduction pathways that regulate cell growth proliferation and differentiation under normal cell function, as well as under abnormal conditions. RTK receptors are overexpressed in several tumors and are directly and indirectly involved in cancer. [123] [124] [125] where they play a pivotal role in tumor angiogenesis. 123, 124 Angiogenesis is the formation of new blood vessels from existing Vasculature, the newly sprouted blood vessels provide supply of nutrients to the tumor to grow beyond 1-2 mm. 126 Angiogenesis is essential step in the transition of solid tumors from a dormant state to a malignant state and it also provides metastatic pathways for solid tumors 127 . Small molecule RTK inhibitors targeting the ATP binding site of tyrosine kinases are currently in clinical use while others are in clinical trials as antitumor agents. [128] [129] [130] There has been considerable discussion in the literature regarding the use of RTK inhibitors for cancer as monotherapy or the combination of multiple RTK inhibitors. Initial strategies for RTK inhibition focused on single RTK inhibitors. However, tumors have redundant signaling pathways for angiogenesis and often develop resistance to agents that target one specific pathway. 131 A multitargeted approach that inhibits multiple signaling pathways proved to be more effective than the inhibition of a single target. In 2010 in an attempt to structurally design either a dual EGFR/VEGFR-2 inhibitor or even a selective VEGFR-2 inhibitor, (Compound 43) was previously synthesized as multiple RTK inhibitor, and the VEGFR-2 inhibitor (Compound 47), were chosen for further evaluation and showed significant inhibition of tumor growth, angiogenesis and metastasis. 136 
Compound 47
Another study based on the pyrrolo [3,2-d] pyrimidine derivative mentioned before as potent antiangiogenic kinase inhibitors (Compound 38) was performed. 122 This exhibited inhibitory activities against VEGFR, PDGFR, and Tie-2 with IC50 values of <100 nM but it was a weak inhibitor of FGFR, Since FGF-FGFR signaling has been described as the escape mechanism for resistant tumors to VEGF treatment 137 , Y. Oguro et al. thought of the development of compounds that would inhibit both VEGFR and FGFR to avoid resistance over long-term treatment. Also, these compounds were expected to be more soluble than (Compound 38), which have poor aqueous solubility. Among the compounds synthesized, urea derivative (Compound 48) with a piperazine ring on the terminal benzene ring strongly inhibited FGFR1 kinase as well as VEGFR2 kinase with IC50 values of 14 and 9 nm, respectively. et al., 2018, 2 (1), 1-19 http://aprh.journals.ekb.eg/ 13 compounds were evaluated in cell-based assay for their inhibitory activity against EGFR, VEGFR-1, 2 and PDFGR-b. Minor variations in the substitution on the 4-anilino ring led to significant differences in inhibition of the different RTKs. These variations in activity may be due to the specific requirements for binding in the individual RTKs or due to differences in cell permeability of these structures. (Compound 49) was evaluated in vivo in B16-F10 syngeneic mouse tumor model. In this study a significant reduction in tumor growth rate, vascular density and metastases of the tumor to the lung was observed for this .
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Compound 49
The most recent study in 2017 described the development of a series of novel benzopyrrolopyrimidines as dual inhibitors of both EGFR and VEGFR2. Of the different compounds were identified (Compound 50) exhibited very good kinase inhibitory activity for both targets (EGFR Ki 1.87 uM, VEGFR Ki 0.85 uM). These structures can be used as lead compounds for further drug development studies. 
CONCLUSION
In this review we have provided a comprehensive and up-to-date account on the most recent development in the medicinal chemistry of pyrrolopyrimidine derivatives with significant anticancer activity through inhibition of different kinase enzymes. This review described the various pyrrolopyrimidine derivatives that have been published in the literature. This could provide a guide for a comprehensive and target oriented information for development of clinically approved pyrrolopyrimidinebased anticancer agents for novel anticancer drug discovery starting from the last exhaustive publication in this field. 
